Decubitus ulcers: definitions, disagreements, and deductive etiology.

ing & Indexing: The journal is indexed in Index Medicus/MEDLINE. Pulse Marketing & Communications, LLC 4 Peninsula Avenue • Suite 401 • Sea Bright, NJ 07760 • Tel (732) 747-6525 • Fax (732) 747-7010 Corporate Publishing Editorial BRIEF SUMMARY Rx ONLY INDICATIONS AND USAGE: Naftin® Cream, 1% is indicated for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. Naftin® Gel, 1% is indicated for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans*, Epidermophyton floccosum*. *Efficacy for this organism in this organ system was studied in fewer than 10 infections. CONTRAINDICATIONS: Naftin® Cream and Gel, 1% are contraindicated in individuals who have shown hypersensitivity to any of their components. WARNINGS: Naftin® Cream and Gel, 1% are for topical use only and not for ophthalmic use. PRECAUTIONS: General: Naftin® Cream and Gel, 1%, are for external use only. If irritation or sensitivity develops with the use of Naftin® Cream or Gel, 1%, treatment should be discontinued and appropriate therapy instituted. Diagnosis of the disease should be confirmed either by direct microscopic examination of a mounting of infected tissue in a solution of potassium hydroxide or by culture on an appropriate medium. Information for patients: The patient should be told to: 1. Avoid the use of occlusive dressings or wrappings unless otherwise directed by the physician. 2. Keep Naftin® Cream and Gel, 1% away from the eyes, nose, mouth and other mucous membranes. Carcinogenesis, mutagenesis, impairment of fertility: Long-term studies to evaluate the carcinogenic potential of Naftin® Cream and Gel, 1% have not been performed. In vitro and animal studies have not demonstrated any mutagenic effect or effect on fertility. Pregnancy: Teratogenic Effects: Pregnancy Category B: Reproduction studies have been performed in rats and rabbits (via oral administration) at doses 150 times or more than the topical human dose and have revealed no evidence of impaired fertility or harm to the fetus due to naftifine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Nursing mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Naftin® Cream or Gel,1% are administered to a nursing woman. Pediatric use: Safety and effectiveness in pediatric patients have not been established. ADVERSE REACTIONS: During clinical trials with Naftin® Cream, 1%, the incidence of adverse reactions was as follows: burning/stinging (6%), dryness (3%) erythema (2%), itching (2%), local irritation (2%). During clinical trials with Naftin® Gel, 1%, the incidence of adverse reactions was as follows: burning/stinging (5.0%), itching (1.0%), erythema (0.5%), rash (0.5%), skin tenderness (0.5%). Manufactured for Merz Pharmaceuticals, Greensboro, NC 27410 © 2010 Merz Pharmaceuticals Rev 3/10 skinmedbriefPI.indd 1 4/5/10 4:50 PM GENERAL COUNSEL Marianne Mckenzie [email protected] SAVE THE DATE FOR THE 7th Annual Maui Derm A Pan-Pacifi c Thought Leaders Meeting FEBRUARY 23-27, 2011 GRAND WAILEA, MAUI Save the Date & Register Early! $395 before June 30th! Plan to attend the 7th Annual Maui Derm Conference! “Cutting edge, a great blend of science and clinical medicine and a world class faculty” describe Maui Derm 2011. Our faculty will share with you the most important developments in medical and cosmetic dermatology vital to your practice. Our live patient demonstration workshops in lasers, Botulinum Toxin A and fi llers have set the standard for “hands on” workshops. Our format has been specifi cally designed to allow optimal time for discussion with our faculty. We are certain that you will fi nd this to be an outstanding and memorable educational event that you will not want to miss. Put Maui Derm on your calendar for 2011! FEATURED LECTURES Medical Dermatology Skin Cancer/Chemoprevention • Acne/Rosacea • Pediatric Dermatology • Infectious Diseases • Psoriasis • Pigmentary Disorders • Contact Dermatitis • Cosmeceuticals • Collagen Vascular Diseases • Offi ce Surgery Tips Practice Management • Skin of Color Cosmetic Dermatology Botulinum Toxin A and Fillers • Lasers • Skin of Color “Lunch with the Faculty” – Controversial Topics, Case-based Discussions Interactive Workshops Small Group, Live Patient, Hands-On Demonstrations: Botulinum Toxins/Fillers Maui Derm 2011 has special/reduced rates at the Grand Wailea and the Wailea Marriott For more details, visit our website at www.acmd-derm-hawaii.com MAUI DERM 2011 FACULTY Chairman: Dr. George Martin Dr. Rox Anderson Dr. Andrew Blauvelt Dr. Joel Cohen Dr. Lawrence Eichenfi eld Dr. Ilona Frieden Dr. Sheila Fallon-Friedlander Dr. Michael Gold Dr. Mitchel Goldman Dr. Pearl Grimes Dr. Arthur Kavanaugh Dr. Suzanne Kilmer Dr. David Laub Dr. Craig Leonardi Dr. Stuart Maddin Dr. Sam Moschella Dr. Stuart Nelson Dr. Kevin Pinski Dr. Ted Rosen Dr. Vic Ross Dr. Alan Shalita Dr. Bruce Strober Dr. Hensin Tsao Dr. Sandy Tsao Dr. Guy Webster Dr. Philip Werscheler